| Date | Title | Description |
| 31.05.2024 | Forbion's Billion-Dollar Sale to Johnson & Johnson: A Landmark Achievement in Biotech Innovation | The recent announcement of Forbion's sale of Yellow Jersey Therapeutics to Johnson & Johnson for a staggering $1.25 billion has sent shockwaves through the biotech industry. This monumental deal, which includes the acquisition of rights... |
| 28.05.2024 | Forbion Announces $1.25 Billion Sale to Johnson & Johnson of Numab Therapeutics Subsidiary, Including Rights to NM26, a Bi-specific Antibody for the Treatment of Atopic Dermatitis, Marking its Six... | • Forbion announces the sale of Yellow Jersey Therapeutics, a wholly owned subsidiary to be spun off from its portfolio company Numab Therapeutics, an investment of Forbion’s Growth Opportunities Fund I
• This is Forbion's sixth consecutive... |
| 16.05.2024 | enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors | BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder c... |
| 02.05.2024 | Forbion Portfolio Company Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer | • Latest deal marks the fifth Forbion portfolio company to be acquired for over $1 bn within a year
Naarden, The Netherlands, 2 May 2024 - Forbion portfolio company Mariana Oncology (Mariana) is to be acquired by Novartis for $1 billion in ... |
| 30.10.2023 | Entrepreneur of the Year Award für Urban Connect und VectivBio Gründer | |
| 08.09.2023 | Startups und Scaleups im Finale des EY Entrepreneur Of The Year | |
| 23.05.2023 | Ironwood Pharma to acquire VectivBio for more than USD 1 billion | |
| 16.03.2023 | VectivBio and its partner conduct Japan-centric clinical trial | |
| 20.10.2022 | VectivBio raises $125 million | |
| 13.10.2022 | VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares | BASEL, Switzerland, Oct. 13, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the... |
| 13.10.2022 | VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares | - |
| 13.10.2022 | VectivBio Announces Pricing of $125 Million Underwritten Offering of Ordinary Shares | - |
| 05.07.2022 | VectivBio Announces Closing of $54 Million Aggregate Financing | |
| 29.06.2022 | VectivBio Announces Closing of $54 Million Aggregate Financing | BASEL, Switzerland, June 29, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, announces it has cl... |
| 15.06.2022 | Forbion Growth Opportunities Fund II leads USD 50 million placement of VectivBio | Amsterdam, The Netherlands, 15 June 2022 -- Forbion, a leading European life sciences venture capital firm, announces that its Forbion Growth Opportunities Fund II has entered into a subscription and share purchase agreement with VectivBio ... |
| 14.06.2022 | VectivBio Announces Pricing of $30 Million Public Offering of Ordinary Shares | BASEL, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced the... |
| 05.04.2022 | VectivBio signs a $117m Japan exclusive license deal and loan facility agreement | |
| 30.03.2022 | Luca Santarelli's VectivBio bags $100M-plus in new funding from licensing pact, loan | Luca Santarelli’s rare disease player VectivBio, just three years out from being founded by the Roche vet and just a year after going public on Nasdaq in a $127.5 million IPO, is looking to raise more capital. And by the looks of it, the bi... |
| 21.09.2021 | VectivBio : R&D Day presentation | VectivBio R&D Day
September 21, 2021
CONFIDENTIAL
Disclaimer and Forward-Looking Statements
This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 tha... |
| 06.09.2021 | VectivBio expands drug pipeline | VectivBio (Nasdaq: VECT) is a global, clinical-stage biotechnology company focused on discovering, developing, and commercialising innovative treatments for severe rare conditions. to expand its drug pipeline. The company has acquired Comet... |
| 31.08.2021 | VectivBio : to Acquire Comet Therapeutics and Host R&D Day | - Acquisition of Innovative Small Molecule Platform Significantly Expands Rare Disease Pipeline -
- VectivBio to Host R&D Day on September 21, 2021-
BASEL, Switzerland, Aug. 31, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”... |
| 31.08.2021 | VectivBio : Acquisition of Innovative Small Molecule Platform Significantly Expands Rare Disease Pipeline (Form 6-K) | - Acquisition of Innovative Small Molecule Platform Significantly Expands Rare Disease Pipeline -
- VectivBio to Host R&D Day on September 21, 2021-
BASEL, Switzerland, August 31, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG ('VectivBi... |
| 14.04.2021 | VECTIVBIO HOLDING AG
CORRECTION – VectivBio Announces Closing of $146.6 Million Initial Public Offering | BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- In a press release issued under the same headline earlier today by VectivBio Holding AG (Nasdaq: VECT), please note that in the first sentence of the first paragraph, the figure of the ... |
| 14.04.2021 | VECTIVBIO HOLDING AG
VectivBio Announces Closing of $146.6 Million Initial Public Offering | BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative trea... |
| 12.04.2021 | VectivBio with strong debut on Nasdaq | |
| 12.04.2021 | VectivBio with strong debut on Nasdaq | Although VectivBio was founded only In 2019, the company has already one product candidate in Phase III clinical trials. Apraglutide is a therapeutic for a range of rare gastrointestinal diseases, with an initial focus on short bowel syndro... |
| 10.02.2021 | VectivBio Announces Start of Phase 3 Trial | |
| 10.02.2021 | VectivBio Announces Start of Phase 3 Trial | The phase 3 STARS (STudy of ApRaglutide in SBS) trial is a global clinical trial that represents the largest phase 3 trial ever conducted in short bowel syndrome with intestinal failure (SBS-IF). STARS is the first trial of a next-generatio... |
| 03.02.2021 | VectivBio Announces First Patient Dosed in Pivotal Phase 3 Trial of Apraglutide for the Treatment of Short Bowel Syndrome | |
| 30.12.2020 | New board members to accelerate growth | |
| 30.12.2020 | New board members to accelerate growth | Exnaton, an ETH spinoff providing a software platform (PowerQuartier) for energy communities, welcomed Kurt Lüscher as its first external board member. Lüscher has led various CEO roles at six companies. He was recently at Energie 360° AG w... |
| 19.10.2020 | VectivBio Closes $110M Crossover Financing | VectivBio AG, a Basel, Switzerland-based clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, closed a $110m crossover financing.
Backers included new investors Surveyor Capital... |
| 19.10.2020 | VectivBio secures $110 million to finance Phase III clinical trials | |
| 19.10.2020 | VectivBio secures $110 million to finance Phase III clinical trials | VectivBio closed a $110 million crossover financing from new investors Surveyor Capital (a Citadel company), Cormorant Capital and Eventide Asset Management, with participation from existing investors Versant Ventures, OrbiMed, Novo Holding... |
| 15.10.2020 | VectivBio Closes $110 Million Crossover Financing to Advance Transformational Medicines for Rare Diseases | - |
| 15.10.2020 | VectivBio Closes $110 Million Crossover Financing to Advance Transformational Medicines for Rare Diseases | |
| 09.01.2020 | Therachon spin-off launches with $35 million investment | |
| 09.01.2020 | Therachon spin-off launches with $35 million investment | VectivBio, a clinical-stage biotechnology company, is bringing transformational medicines to patients with serious rare diseases. The company announced its formation with $35 million in financing including commitments by Versant Ventures, O... |
| 07.01.2020 | VectivBio Launches with $35M Financing to Bring Best-in-Disease Medicines to Patients with Serious Rare Diseases | - |
